RT Journal Article
SR Electronic
T1 Active vaccine safety surveillance via a scalable, integrated system in Australian pharmacies
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.14.20248212
DO 10.1101/2020.12.14.20248212
A1 Salter, Sandra M
A1 Singh, Gurkamal
A1 Nissen, Lisa
A1 Trentino, Kevin
A1 Murray, Kevin
A1 Lee, Kenneth
A1 Kop, Benjamin
A1 Peters, Ian
A1 Leeb, Alan
YR 2020
UL http://medrxiv.org/content/early/2020/12/16/2020.12.14.20248212.abstract
AB Introduction Active vaccine safety surveillance will be critical to COVID-19 vaccine deployment. Pharmacists have been identified as potential immunisers in COVID-19 policies, yet there are no reported active surveillance systems operating in pharmacies. We integrated an established participant-centred active vaccine safety surveillance system with a cloud-based pharmacy immunisation-recording program. We measured adverse events following immunisation (AEFI) reported via the new surveillance system in pharmacies, and compared these to AEFI reported via an existing surveillance system in non-pharmacy sites (general practice and other clinics).Methods A prospective cohort study of individuals>10 years receiving influenza immunisations from 22 pharmacies and 90 non-pharmacy sites between March and October, 2020, in Australia. Active surveillance was conducted using SMS and smartphone technology, via an opt-out system. Multivariable logistic regression (including a subgroup analysis of participants over 65 years) was used to assess differences in proportions of AEFI between participants immunised in pharmacies compared to non-pharmacy sites, adjusting for confounders of age, sex, and influenza vaccine brand.Results Of 101,440 influenza immunisation participants (6,992 from pharmacies; 94,448 from non-pharmacy sites), 77,498 (76.4%) responded; 96.1% (n=74,448) within 24 hours. Overall, 4.8% (n=247) pharmacy participants reported an AEFI, compared with 6.0% (n=4,356) non-pharmacy participants (adjusted odds ratio: 0.87; 95% confidence interval: 0.76 to 0.99; p=0.039). Similar proportions of AEFIs were reported in pharmacy (5.8%; n=31) and non-pharmacy participants (6.0; n=1617) aged over 65 years (adjusted odds ratio: 0.94, 95% confidence interval: 0.65 to 1.35; p=0.725).Conclusion High and rapid response rates demonstrate good participant engagement with active surveillance in both pharmacy and non-pharmacy participants. Significantly fewer AEFIs reported after pharmacist immunisations compared to non-pharmacy immunisations, with no difference in older adults, suggests different cohorts attend pharmacy and non-pharmacy immunisers. The integrated pharmacy system is rapidly scalable across Australia with global potential.What is already known?Many countries use post-licensure surveillance systems to monitor vaccine safety after a vaccine has been released onto the market.Passive surveillance systems operate in most countries but are limited by under- and/or biased reporting, and delayed detection of safety signals.Active surveillance systems have been reported for different sectors in Australia, the United States and Canada but there are no pharmacy-based active surveillance systems world-wide, and there is little evidence of rates of adverse events following immunisation (AEFI) in pharmacy.What are the new findings?We successfully linked two established platforms: an active vaccine safety surveillance system that integrates with national surveillance networks in Australia, with a cloud-based pharmacy immunisation-record system to develop an automated active vaccine safety surveillance system for pharmacies.Through active surveillance of 101,440 influenza immunisations between March and October, 2020 (6,992 from pharmacies, and 94,448 from non-pharmacy sites), fewer pharmacy participants reported any AEFI compared to non-pharmacy participants.What do the new findings imply?Pharmacists are safe immunisers who may capture patients not seen in general practice or other clinics.Our integrated pharmacy system is rapidly scalable, links with existing surveillance systems that integrate with the World Health Organization and has global potential.This study provides a proven infrastructure of crucial importance to maintain public safety, to promote confidence in vaccine safety, and to assist with COVID-19 vaccine uptake in a safe manner.Competing Interest StatementSMS, AL, KL, LN, IP report a grant from the J.M. OHara Research Fund of the Pharmaceutical Society of Western Australia (PSWA) to conduct this research. AL and IP are Directors of SmartXData, of which SmartVax is a subsidiary. IP has previously received funding from SmartX Data for database development. The authors declare no other conflicts.Funding StatementThe study was supported by a research grant provided by the J.M. OHara Research Fund of the Pharmaceutical Society of Western Australia. The funders of this study had no role in the study design, data collection, analysis, interpretation, recruitment or writing of the report. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval for this study was obtained from The University of Western Australia Human Research Ethics Committee (RA/4/20/5907).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual participant data that underlie the results reported in this article, after de-identification (text, tables, figures, and supplementary material) are available upon reasonable request. Proposals for data should be directed to Sandra Salter via ORCID: https://orcid.org/0000-0002-5840-6797. To gain access to data, users will need to sign a data access agreement. Reuse is permitted under the following conditions: meta-analyses of adverse events following immunisation in pharmacies.